Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA
What you need to know
Bimekizumab – a monoclonal antibody that inhibits both interleukin (IL)-17A and IL-17F – has shown promise in phase 3 trials across the spectrum of spondyloarthritis. Take a look at this page for a quick-reference summary of the data in psoriatic arthritis and axial spondyloarthritis, expert opinion on what the trial results might mean for clinical practice, and the latest news on research and regulatory approvals.
Phase 3 trials of bimekizumab in PsA
Phase 3 trials of bimekizumab in axSpA